Geographic Atrophy Secondary to Age-related Macular Degeneration
Conditions
Brief summary
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Interventions
DRUGAPL-3007, pegcetacoplan (APL-2)
Complement C3 inhibitor
OTHERPlacebo, Syfovre
Complement C3 Inhibitor
Sponsors
Apellis Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with better normal luminance visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be used as the study eye. * Aged ≥60 years * Clinical diagnosis of GA of the macula secondary to AMD in one or both eyes, as determined by the investigator and confirmed by the reading center * NL-BCVA of 50 letters or better using early treatment diabetic retinopathy study (ETDRS) charts (approximately 20/100 Snellen equivalent) * Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images in the study eye as determined by the investigator * Prior treatment for GA in the study eye using Syfovre at 6-8 weeks interval for at least 6 months but no more than 24 months. Participants will be included if the participant has had at least 2 Syfovre injections in the last 6 months before screening. * The GA lesion in at least 1 eye (designated as the study eye) must meet the following criteria as determined by the central reading center's OCT based RPE assessment of imaging at screening: * Total GA area must be ≥2.5 and ≤17.5 mm2 (1-7 disk areas \[DA\]) * If GA is multifocal, at least 1 focal lesion must be ≥1.25 mm2 (0.5 DA), with the overall aggregate area of GA as specified above in 7a * The entire GA lesion must be completely visualized in the field of view of the OCT, with the GA RPE lesion border \>500 µm from the edge of the imaging window or any areas of peripapillary atrophy. * Nonsubfoveal lesion with border of GA lesion not encroaching center of the fovea. Distance of GA RPE lesion from center of the fovea \>0 based on OCT imaging. * Presence of any pattern of hyperautofluorescence based on FAF imaging in the junctional zone of GA. Absence of hyperautofluorescence (ie, pattern = none) is exclusionary. * Documented evidence of vaccination within 5 years prior to screening, or willing to initiate vaccinations at least 14 days prior to dosing against: * Streptococcus pneumoniae (with a pneumococcal conjugate vaccine 15 \[PCV15\] or 20 \[PCV20\] or with pneumococcal polysaccharide vaccine 23 \[PPSV23\]), * Haemophilus influenzae (type B) (with Hib vaccine), * Neisseria meningitidis types A, C, W, and Y (with a quadrivalent meningococcal conjugate vaccine \[eg, Menactra or MenQuadfi\]), and * Neisseria meningitidis type B (with a meningococcal serogroup B vaccine \[eg, Bexsero\]) Female participants must be: * Women of non-childbearing potential (WONCBP), or * Women of childbearing potential (WOCBP) with a negative serum pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study and refrain from breastfeeding for the duration of the study (see Section 10.9.5.1) Male participants must be surgically sterile or must agree to use highly effective contraception from screening through the duration of the study Willing and able to provide informed consent and adhere to the study visit schedule and other protocol requirements
Exclusion criteria
1. Uncontrolled, clinically relevant history of any gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological or allergic disease, metabolic disorder, or cancer 2. History or presence of hepatic cirrhosis or other liver disease that may increase the risk of drug-induced liver injury 3. History or presence of systemic autoimmune disorders, with the exception of well controlled Hashimoto's thyroiditis 4. History of allergy, hypersensitivity, or serious adverse reaction to siRNA therapy or related compounds, or allergy to any of the components of the study drug 5. Clinically meaningful abnormalities on diagnostic and laboratory testing must be adjudicated by the sponsor's medical monitor and include: 1. Cardiac Sustained resting heart rate outside of range of 40 to 100 beats/minute, or a heart rhythm that is not sinus rhythm, confirmed on repeat testing within a maximum of 30 minutes, at screening History or evidence of hereditary short QT syndrome Fridericia's corrected QT interval (QTcF) \>480 milliseconds, or the PR interval outside the range of 120 to 220 milliseconds, confirmed on repeat testing within a maximum of 30 minutes at screening Any clinically relevant features of acute coronary syndrome (unstable angina, myocardial infarction) Any other ECG parameters outside of age-adjusted normative range 2. Hepatic AST or ALT \>1.3 × ULN Total bilirubin \>1.1 × ULN Any 2 LFTs \>1.1 × ULN Any other LFT parameters outside of age-adjusted normative range 3. Renal Estimated glomerular filtration rate of less than \<45 mL/min/m2 as calculated by the Chronic Kidney Disease-Epidemiology Collaboration (CKD- EPI) creatinine equation for adults Any other renal function parameters outside of age-adjusted normative range 6. History or presence of malignancy (except history of basal or squamous cell carcinoma of the skin) that has not been successfully treated ≥1 year prior to enrollment 7. History or presence of recurrent or unexplained infections, HIV infection, hepatitis B, hepatitis C, or meningococcal infection 8. Participants with fever (defined as temperature \>100.4 °F/38 °C) or any acute infection (including COVID-19 infection or infection requiring antibiotic treatment) within 30 days of screening until dosing 9. Evidence of ongoing drug or alcohol abuse or dependence, in the opinion of the investigator 10. Intention to donate sperm during this study or within 90 days after the last dose of study drug 11. Prior administration of APL-3007 12. Participation in an investigational product or medical device study within 5 half-lives of the investigational product before the screening visit 13. Has poor peripheral venous access or any abnormal skin conditions or potentially obscuring tattoos, pigmentation, or lesions in the area intended for SC injection that would interfere with SC injections or assessments of injection local tolerability 14. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the investigator or medical monitor(s), unacceptably increase the participant's risk by participating in the study 15. Has received a live vaccination (excluding seasonal flu vaccination) within 30 days prior to the first dose administration 16. Women who are pregnant or breastfeeding 17. Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the treatment period unlikely, or would make the participant an unsafe study candidate Ocular specific
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the study eye | At month 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CFB in the area of AI-based OCT assessment of photoreceptor degeneration in the study eye | At month 12 | — |
| Safety & tolerability based on adverse event (AE) reporting | At month 12 | — |
| Safety as assessed by Best Corrected Visual Acuity (BCVA) | At Month 12 | Continuous monitoring of a subject' BCVA as assessed by EDTRS chart |
| Change from baseline in Serum C3 level | At Month 12 | Continuous monitoring of a subject's Serum C3 level |
| CFB in RPE lesion area as assessed by FAF in the study eye | At month 12 | — |
| CFB in the junctional zone, central 2o and 6o MP number of scotomatous points in the study eye | At month 12 | — |
| CFB in the junctional zone, central 2o and 6o MP mean sensitivities in the study eye | At month 12 | — |
| CFB in normal luminance qCSF in the study eye as assessed with the Adaptive Sensory Technology Manifold Platform | At month 12 | — |
| CFB in low luminance qCSF in the study eye as assessed with the Adaptive Sensory Technology Manifold platform | At month 12 | — |
Countries
United States
Contacts
CONTACTApellis Clinical Trial Information Line
Outcome results
None listed